BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16574037)

  • 1. Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules.
    Nicholson B; Ross E; Weil A; Sasaki J; Sacks G
    Curr Med Res Opin; 2006 Mar; 22(3):539-50. PubMed ID: 16574037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain.
    Nicholson B; Ross E; Sasaki J; Weil A
    Curr Med Res Opin; 2006 Aug; 22(8):1503-14. PubMed ID: 16870075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting dosing regimens of morphine sulfate extended-release (KADIAN) capsules.
    Weil AJ; Nicholson B; Sasaki J
    J Opioid Manag; 2009; 5(1):39-45. PubMed ID: 19344047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions--the ACCPT Study.
    Adams EH; Chwiecko P; Ace-Wagoner Y; Mangefrida B; Duerden ME; Perdikis GC; Kunkel FA; Ghalie R
    Pain Pract; 2006 Dec; 6(4):254-64. PubMed ID: 17129306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.
    Katz N; Hale M; Morris D; Stauffer J
    Postgrad Med; 2010 Jul; 122(4):112-28. PubMed ID: 20675975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
    Katz N; Sun S; Johnson F; Stauffer J
    J Pain; 2010 Apr; 11(4):303-11. PubMed ID: 19944650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KADIAN (morphine sulfate extended-release) capsules for treatment of chronic, moderate-to-severe, nonmalignant pain.
    Ross EL; Hahn K
    Int J Clin Pract; 2008 Mar; 62(3):471-9. PubMed ID: 18261077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of Kadian (morphine sulfate sustained-release capsules) in patients with chronic, nonmalignant pain.
    Chao J
    Pain Med; 2005; 6(3):262-5. PubMed ID: 15972090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients.
    Vorsanger G; Xiang J; Jordan D; Farrell J
    Clin Ther; 2007; 29 Suppl():2520-35. PubMed ID: 18164919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of oxycodone controlled-release immediately after NSAIDs: a new approach to obtain good pain control.
    Tessaro L; Bandieri E; Costa G; Fornasier G; Iorno V; Pizza C; Pastacaldi G; Micheletto G
    Eur Rev Med Pharmacol Sci; 2010 Feb; 14(2):113-21. PubMed ID: 20329570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of mirtazapine in patients with chronic pain and concomitant depression.
    Freynhagen R; Muth-Selbach U; Lipfert P; Stevens MF; Zacharowski K; Tölle TR; von Giesen HJ
    Curr Med Res Opin; 2006 Feb; 22(2):257-64. PubMed ID: 16466597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsules.
    Webster LR; Brewer R; Morris D; Cleveland JM; Setnik B
    Postgrad Med; 2011 Sep; 123(5):155-64. PubMed ID: 21904098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
    Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
    Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
    Matsumoto AK; Babul N; Ahdieh H
    Pain Med; 2005; 6(5):357-66. PubMed ID: 16266356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.